Market Place
Sourcing Support
EMA Approves Safety Updates for Kite`s Yescarta, Tecartus
24 Apr 2026 //
FIRSTWORD PHARMA
Gilead Loosens Ties To Arcus As TIGIT Dream Ends In Ph. 3 Fail
21 Apr 2026 //
FIERCE BIOTECH
Kymera Announces Gilead’ Option Exercise to License KT-200
10 Apr 2026 //
ENDPOINTS NEWS
Cartography`s Strategic First Option Target Exercise with Gilead
09 Apr 2026 //
PHARMIWEB
Tempus Announces Collab with Gilead to Advance Oncology R&D
09 Apr 2026 //
BUSINESSWIRE
Gilead Pays Kymera $45M For Preclinical Protein Degrader
09 Apr 2026 //
FIERCE BIOTECH
Gilead to buy Germany`s Tubulis for up to $5 billion
07 Apr 2026 //
PRESS RELEASE
Gilead Cancels HIV Trial As Clinical Hold Remains Intact
01 Apr 2026 //
FIERCE BIOTECH
Gilead Sciences to Acquire Ouro Medicines
26 Mar 2026 //
BUSINESSWIRE
Gilead Sciences to Acquire Ouro Medicines for Autoimmune Diseases
23 Mar 2026 //
BUSINESSWIRE
Gilead Turns Down Assembly`s Ph. 1-Stage HBV Antiviral
21 Mar 2026 //
FIERCE BIOTECH
Gilead Turns Down Assembly`s Ph. 1-Stage HBV Antiviral
20 Mar 2026 //
FIERCE BIOTECH
Manufacturing Is Key To Gilead`s Yeztugo Prep Rollout: Exec
13 Mar 2026 //
FIERCE PHARMA
One2PrEP`: Gilead`s 1st Yeztugo ad highlights biannual dosing
02 Mar 2026 //
FIERCE PHARMA
Gilead, Merck Clear Path for Daily HIV Pills with Late-Stage Data
26 Feb 2026 //
BIOSPACE
Gilead experimental HIV treatment shows Low discontinuation rate
26 Feb 2026 //
REUTERS
Gilead`s Bictegravir/Lenacapavir Sustains HIV Virologic Control
25 Feb 2026 //
BUSINESSWIRE
Gilead To Unveil HIV Treatment And Prevention Data At CROI 2026
17 Feb 2026 //
BUSINESSWIRE
Gilead in licensing deal with Chinese biotech for cancer therapy
16 Feb 2026 //
FIERCE BIOTECH
‘Pieces are coming together’ amid Gilead`s Yeztugo launch
11 Feb 2026 //
FIERCE PHARMA
The Biggest Potential Drug Launches Of 2026
06 Feb 2026 //
FIERCE PHARMA
Gilead`s Yescarta Approved For Expanded Patient Use
06 Feb 2026 //
FIERCE PHARMA
NEJM: Ph 3 ASCENT-04/KEYNOTE-D19 Trodelvy+Keytruda Supports SoC
21 Jan 2026 //
BUSINESSWIRE
Onconano, Gilead Partner To Apply ON-BOARD Tech To Drug
06 Jan 2026 //
BUSINESSWIRE
Abbvie, Gilead Gift Themselves Clinical-Stage Cancer Drugs
02 Jan 2026 //
FIERCE BIOTECH
Gilead Licenses Assembly Bio`s Herpes Drugs After Positive Phase
24 Dec 2025 //
INDPHARMAPOST
Gilead pays $35M to license pair of HSV assets from Assembly Bio
24 Dec 2025 //
BUSINESSWIRE
Gilead`s HIV Single-Tablet Regimen Meets Phase 3 Trial Goal
15 Dec 2025 //
BUSINESSWIRE
Arcus Updates Phase 3 STAR-221 Study, Focuses R&D On Casdatifan
12 Dec 2025 //
PHARMIWEB
Gilead, J&J Lead CAR-T In Multiple Myeloma; Fulcrum Soars
08 Dec 2025 //
BIOSPACE
Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
Kite Next-Gen Bicistronic CAR-T Shows Ph1 Promise in Lymphoma
06 Dec 2025 //
BUSINESSWIRE
Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma
06 Dec 2025 //
BUSINESSWIRE
Gilead Launches Innovative HIV Prevention Drug In Eswatini
25 Nov 2025 //
INDPHARMAPOST
Gilead Hatches $400M Biobucks Deal For Sprint`s TREX1 Program
24 Nov 2025 //
FIERCE BIOTECH
Merck`s Two-Drug HIV Regimen Hits Phase 3 Success
20 Nov 2025 //
PRESS RELEASE
Merck`s HIV Combo Matches Gilead`s Biktarvy In Phase 3 Test
19 Nov 2025 //
BUSINESSWIRE
Galapagos Urged By Gilead To Avoid Extinction
19 Nov 2025 //
FIERCE BIOTECH
Gilead`s Bictegravir, Lenacapavir Tablet Meets Mark In Phase 3
13 Nov 2025 //
BUSINESSWIRE
J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T
12 Nov 2025 //
FIERCE PHARMA
Gilead Provides Update On Phase 3 ASCENT-07 Study
07 Nov 2025 //
BUSINESSWIRE
Gilead And Kite Show Progress In Blood Cancer Cell Therapy Data
03 Nov 2025 //
BUSINESSWIRE
Gilead Lifts Guidance on Prep Launch Despite Cell Therapy Woes
31 Oct 2025 //
FIERCE PHARMA
Gilead to Present Livdelzi and Bulevirtide Efficacy Data
23 Oct 2025 //
BUSINESSWIRE
Gilead`s Trodelvy Cuts Breast Cancer Risk by 38% in Trial
20 Oct 2025 //
REUTERS
Kite Puts $1.64B On Line For Pregene`s In Vivo CAR-T Deal
20 Oct 2025 //
FIERCE BIOTECH
Gilead To Present Latest Virology Data At IDWEEK 2025
19 Oct 2025 //
BUSINESSWIRE
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
GSK Tout Study Showing Tolerability Edge for Its Long-Acting PrEP
15 Oct 2025 //
FIERCE PHARMA
Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data
14 Oct 2025 //
INDPHARMAPOST
Gilead, Kite Showcase Cancer Care Transformation At ESMO 2025
13 Oct 2025 //
BUSINESSWIRE
Gilead, Arcus Keep TIGIT Dream Alive With 27-Month OS Data
13 Oct 2025 //
FIERCE BIOTECH
Marengo Therapeutics Expands STARt-002 Trial to Phase 2
18 Sep 2025 //
PR NEWSWIRE
Xilio Starts Ph 2 XTX301 Trial, Hits $17.5M Gilead Milestone
09 Sep 2025 //
GLOBENEWSWIRE
IDEAYA Reveals Ph 1/2 Trial Data of IDE397 & Trodelvy in Cancer
08 Sep 2025 //
PR NEWSWIRE
EU approves Gilead`s new injection for preventing HIV
27 Aug 2025 //
REUTERS
Gilead Ends Last MASH Program, Drops 2 Cancer Assets
08 Aug 2025 //
FIERCE BIOTECH
Gilead`s CAR-Ts Yescarta, Tecartus Sales Drop by 7%
08 Aug 2025 //
FIERCE PHARMA
Lilly`s Kisunla, Gilead`s Pr Ep Drug Yeytuo Gain CHMP Nods
25 Jul 2025 //
FIERCE PHARMA
Gilead Gets CHMP Nod for Lenacapavir HIV Prevention
25 Jul 2025 //
BUSINESSWIRE
